Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Operating Leases: 2020-2024

Historic Operating Leases for Gyre Therapeutics (GYRE) over the last 5 years, with Dec 2024 value amounting to $885,000.

  • Gyre Therapeutics' Operating Leases fell 51.04% to $539,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $539,000, marking a year-over-year decrease of 51.04%. This contributed to the annual value of $885,000 for FY2024, which is 344.72% up from last year.
  • As of FY2024, Gyre Therapeutics' Operating Leases stood at $885,000, which was up 344.72% from $199,000 recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Operating Leases ranged from a high of $981,000 in FY2020 and a low of $121,000 during FY2022.
  • Its 3-year average for Operating Leases is $401,667, with a median of $199,000 in 2023.
  • In the last 5 years, Gyre Therapeutics' Operating Leases tumbled by 70.34% in 2022 and then spiked by 344.72% in 2024.
  • Yearly analysis of 5 years shows Gyre Therapeutics' Operating Leases stood at $981,000 in 2020, then crashed by 58.41% to $408,000 in 2021, then slumped by 70.34% to $121,000 in 2022, then spiked by 64.46% to $199,000 in 2023, then soared by 344.72% to $885,000 in 2024.